N
Norman Zinner
Researcher at Northwestern University
Publications - 42
Citations - 3391
Norman Zinner is an academic researcher from Northwestern University. The author has contributed to research in topics: Overactive bladder & Trospium chloride. The author has an hindex of 25, co-authored 42 publications receiving 3265 citations. Previous affiliations of Norman Zinner include Cornell University & Henry Ford Hospital.
Papers
More filters
Journal ArticleDOI
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Matthew R. Smith,James A. Eastham,Donald M. Gleason,Daniel Shasha,Simon Tchekmedyian,Norman Zinner +5 more
TL;DR: In this paper, a multicenter double-blind, randomized, placebo controlled clinical trial was performed to assess the effect of zoledronic acid, a potent new bisphosphonate, on bone mineral density during androgen deprivation therapy for nonmetastatic prostate cancer.
Journal ArticleDOI
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
Matthew R. Smith,Fairooz F. Kabbinavar,Fred Saad,Arif Hussain,Marc Gittelman,David L. Bilhartz,Chris Wynne,Robin Murray,Norman Zinner,Claude Schulman,Ronald Linnartz,Ming Zheng,Carsten Goessl,Y. J. Hei,Eric J. Small,Richard J. Cook,Celestia S. Higano +16 more
TL;DR: Men with nonmetastatic prostate cancer and rising PSA despite androgen deprivation therapy have a relatively indolent natural history and baseline PSA and PSA velocity independently predict time to first bone metastasis and survival.
Journal ArticleDOI
Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence.
Roger R. Dmochowski,Peter K. Sand,Norman Zinner,Marc Gittelman,G. Willy Davila,Steven W. Sanders +5 more
TL;DR: OXY-TDS improves systemic safety with regard to anticholinergic side effects and TOL-LA are effective and comparable treatments for patients with urge and mixed incontinence.
Journal ArticleDOI
Prospective Randomized Controlled Trial of Extended-Release Oxybutynin Chloride and Tolterodine Tartrate in the Treatment of Overactive Bladder: Results of the OBJECT Study
Rodney A. Appell,Peter K. Sand,Roger R. Dmochowski,Rodney U. Anderson,Norman Zinner,Daniel J. Lama,Martha Roach,John R. Miklos,Daniel Saltzstein,Timothy B. Boone,David R. Staskin,Detlef Albrecht +11 more
TL;DR: Extended-release oxybutynin was more effective than tolterodine as measured by end-of-study urge incontinence, total incentinence, and micturition frequency episodes.
Journal ArticleDOI
A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials
Annabel Nixon,Shoshana Colman,Luann Sabounjian,Bobby W. Sandage,Ute Schwiderski,David R. Staskin,Norman Zinner +6 more
TL;DR: IUSS is a validated patient reported measure of urgency severity for collecting event specific information in the context of a clinical trial and had a significant positive association with essential clinical and quality of life outcomes.